; Corcept Therapeutics Incorporated – Product Pipeline Review – H2 2011
Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out
Your Federal Quarterly Tax Payments are due April 15th Get Help Now >>

Corcept Therapeutics Incorporated – Product Pipeline Review – H2 2011

VIEWS: 3 PAGES: 71

Corcept Therapeutics Incorporated – Product Pipeline Review – H2 2011 Summary Global Market Direct’s pharmaceuticals report, “Corcept Therapeutics Incorporated - Product Pipeline Review - H2 2011” provides data on the Corcept Therapeutics Incorporated’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Corcept Therapeutics Incorporated’s corporate website, SEC filings, investor presentations and featured press releases, both from Corcept Therapeutics Incorporated and industry-specific third party sources, put together by Global Markets Direct’s team. Scope - Corcept Therapeutics Incorporated - Brief Corcept Therapeutics Incorporated overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of Corcept Therapeutics Incorporated human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of Corcept Therapeutics Incorporated with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Corcept Therapeutics Incorporated’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products. Reasons to buy - Evaluate Corcept Therapeutics Incorporated’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Corcept Therapeutics Incorporated in its therapy areas of focus. - Identify ne

More Info
  • pg 1
									Corcept Therapeutics Incorporated – Product Pipeline
Review




 Corcept Therapeutics Incorporated – Product Pipeline
                 Review – H2 2011


                                                                                          Reference Code: GMDHC02132CDB
                                                                                                 Publication Date: DEC 2011




Corcept Therapeutics Incorporated – Product Pipeline Review – H2                          GMDHC02132CDB / Published DEC 2011
2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                               Page(1)
Corcept Therapeutics Incorporated – Product Pipeline
Review



Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 4
    List of Figures ................................................................................................................................................................................ 4
Corcept Therapeutics Incorporated Snapshot .................................................................................................................................... 5
    Corcept Therapeutics Incorporated Overview ............................................................................................................................... 5
    Key Information ............................................................................................................................................................................. 5
    Key Facts....................................................................................................................................................................................... 5
Corcept Therapeutics Incorporated – Research and Development Overview .................................................................................... 6
    Key Therapeutic Areas .................................................................................................................................................................. 6
Corcept Therapeutics Incorporated – Pipeline Review....................................................................................................................... 8
    Pipeline Products by Stage of Development ................................................................................................................................. 8
    Pipeline Products – Monotherapy ................................................................................................................................................. 9
Corcept Therapeutics Incorporated – Pipeline Products Glance ...................................................................................................... 10
    Corcept Therapeutics Incorporated – Late Stage Pipeline .......................................................................................................... 10
        Registration Filed Products/Combination Treatment Modalities.............................................................................................. 10
        Phase III Products/Combination Treatment Modalities ........................................................................................................... 11
    Corcept Therapeutics Incorporated Clinical Stage Pipeline Products.......................................................................................... 12
        Phase II Products/Combination Treatment Modalities ............................................................................................................ 12
    Corcept Therapeutics Incorporated – Early Stage Pipeline Products .......................................................................................... 13
        Pre-Clinical Products/Combination Treatment Modalities ....................................................................................................... 13
Corcept Therapeutics Incorporated – Drug Profiles ......................................................................................................................... 14
    Corlux .......................................................................................................................................................................................... 14
        Product Description................................................................................................................................................................. 14
        Mechanism of Action ............................................................................................................................................................... 14
        R&D Progress ......................................................................................................................................................................... 14
    CORT 113083 ............................................................................................................................................................................. 16
        Product Description................................................................................................................................................................. 16
        Mechanism of Action ............................................................................................................................................................... 16
        R&D Progress ......................................................................................................................................................................... 16
    CORT108297 .............................................................................................................................................................................. 17
        Product Description................................................................................................................................................................. 17
        Mechanism of Action ............................................................................................................................................................... 17
        R&D Progress ......................................................................................................................................................................... 17
    selective GR-II receptor antagonist ............................................................................................................................................. 18
        Product Description................................................................................................................................................................. 18
        Mechanism of Action ............................................................................................................................................................... 18
        R&D Progress ......................................................................................................................................................................... 18
Corcept Therapeutics Incorporated – Pipeline Analysis ................................................................................................................... 19
    Corcept Therapeutics Incorporated – Pipeline Products by Therapeutic Class ........................................................................... 19
    Corcept Therapeutics Incorporated - Pipeline Products By Target .............................................................................................. 20
    Corcept Therapeutics Incorporated – Pipeline Products by Route of Administration................................................................... 21
    Corcept Therapeutics Incorporated – Pipeline Products by Molecule Type ................................................................................ 22


Corcept Therapeutics Incorporated – Product Pipeline Review – H2                                                                         GMDHC02132CDB / Published DEC 2011
2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                        Page(2)
Corcept Therapeutics Incorporated – Product Pipeline Review




Corcept Therapeutics Incorporated – Recent Pipeline Updates ...................................................................................................... 23
Corcept Therapeutics Incorporated - Discontinued Pipeline Products ............................................................................................. 25
    Discontinued Pipeline Product Profiles ........................................................................................................................................ 25
         Corlux ..................................................................................................................................................................................... 25
Corcept Therapeutics Incorporated – Company Statement.............................................................................................................. 26
Corcept Therapeutics Incorporated – Locations And Subsidiaries ................................................................................................... 30
    Head Office.................................................................................................................................................................................. 30
Company's Recent Developments ................................................................................................................................................... 31
    Corcept Therapeutics Incorporated, Recent Developments ........................................................................................................ 31
         Mar 31, 2011: Corcept To Submit NDA For Use Of CORLUX In Cushing’s Syndrome .......................................................... 31
         Jun 30, 2011: FDA Accepts Submission Of New Drug Application For CORLUX For Cushing's Syndrome .......................... 31
         Jun 25, 2010: Corcept Nears Completion Of Enrollment In Phase III Cushing’s Syndrome Study ......................................... 32
         Feb 24, 2010: Corcept Initiates Dosing In Phase I Study Of Selective Cortisol Receptor Antagonist ..................................... 32
         Feb 23, 2009: Data Demonstrates Metabolic Benefits Of Adding Corlux To Treatment With Risperdal ................................. 33
         Dec 22, 2010: Corcept Reports Positive Phase III Study Results For CORLUX In Cushing's Syndrome ............................... 34
         May 19, 2011: Corcept Therapeutics To Present Detailed Findings From CORLUX Phase III Trial In Cushing's Syndrome At
         Endocrine Society's Annual Meeting ....................................................................................................................................... 36
         Apr 15, 2011: Corcept Therapeutics Submits NDA For Use Of Corlux In Cushing’s Syndrome To FDA ................................ 36
         Jan 11, 2011: Corcept Announces Positive Results From Phase III Study Of CORLUX In Cushing's Syndrome .................. 37
         Jan 08, 2009: Corcept Therapeutics Announces Results From Two Preclinical Studies Of CORT 108297 . ......................... 38
         Jun 04, 2011: Corcept Therapeutics Announces Detailed Findings From Phase III Study Which Show CORLUX Significantly
         Improves Clinical And Metabolic Manifestations Of Cushing's Syndrome ....................................................
								
To top